Haemoctin Sdh (Human Coagulation Factor Viii)

Haemoctin Sdh is indicated for the management of bleeding episodes and perioperative prophylaxis in individuals with hemophilia A.

• Treatment of acute bleeding episodes in hemophilia A patients.
• Surgical or dental procedure prophylaxis to prevent excessive bleeding.
• Routine prophylactic therapy to maintain factor VIII activity levels and reduce spontaneous joint bleeds.
• On-demand replacement therapy when factor VIII levels fall below therapeutic thresholds.
• Management of chronic hemophilia A in patients with inhibitors when used in combination with bypassing agents.
• Support for patients undergoing major orthopedic surgery to achieve hemostasis.

The safety profile of Haemoctin Sdh includes both frequently observed and less common adverse reactions.

Common

• Mild fever or chills during infusion.
• Headache or fatigue.
• Local infusion site reactions such as erythema or swelling.
• Nausea or mild abdominal discomfort.
• Transient increase in liver enzymes.
• Mild arthralgia.
• Mild rash or urticaria.
• Transient hypertension during infusion.
• Transient tachycardia.
• Mild dizziness.

Serious

• Development of inhibitors (antibodies) against factor VIII, reducing treatment efficacy.
• Severe allergic reactions including anaphylaxis, bronchospasm, or angioedema.
• Thrombotic events such as deep vein thrombosis or pulmonary embolism (rare).
• Disseminated intravascular coagulation (very rare).
• Renal dysfunction (rare).
• Severe hemolysis (extremely rare).
• Immune complex-mediated vasculitis (very rare).

Precautions for Haemoctin Sdh focus on patient assessment, monitoring, and risk mitigation before and during therapy.

• Verify diagnosis of hemophilia A and baseline factor VIII activity.
• Screen for history of inhibitors or previous allergic reactions to factor VIII products.
• Assess liver and renal function prior to initiation.
• Monitor for signs of inhibitor development during treatment.
• Use caution in patients with cardiovascular disease or a history of thrombosis.
• Ensure appropriate infusion rate to reduce infusion-related reactions.
• Educate patients on recognizing symptoms of severe allergic reactions.

Haemoctin Sdh may interact with other medications that affect hemostasis, immune response, or infusion safety.

Avoid

• Concurrent use of other factor VIII concentrates without medical supervision.
• Administration of bypassing agents in patients with known inhibitors unless specifically indicated.
• Use of high‑dose vitamin K antagonists that may alter coagulation balance.

Use with caution

• Antifibrinolytic agents (e.g., tranexamic acid) may enhance clot stability and should be coordinated.
• Immunosuppressive drugs can affect inhibitor development and require monitoring.
• Concomitant use of drugs that cause hypertension (e.g., vasopressors) may increase risk of infusion reactions.
• Live vaccines should be avoided during active treatment due to potential immune modulation.